”completion of this Phase I trial, NYR-BI03 has the potential to progressdirectly to Phase II trials to assess its efficacy in stroke, traumatic brain injury, and nowmyocardial ischemia-reperfusion injury.”
So this phase 1 about to start shortly takes us straight to phase 2 in myocardial ischemia-reperfusion injury. We don’t need to do another phase 1. Now that’s what I like to hear. GLP micronucleus results are the big ones from GLP and the last ones to be announced shortly to heavily de risk safety.
Ann: Drug Candidate Demonstrates Significant Cardioprotection, page-29
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.010(8.33%) |
Mkt cap ! $20.04M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.0¢ | 11.0¢ | $72.78K | 624.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 302090 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| NYR (ASX) Chart |